These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764 [TBL] [Abstract][Full Text] [Related]
3. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Hampp C; Kauf TL; Saidi AS; Winterstein AG Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647 [TBL] [Abstract][Full Text] [Related]
5. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Schrand LM; Elliott JM; Ross MB; Bell EF; Mutnick AH Ann Pharmacother; 2001 Oct; 35(10):1186-93. PubMed ID: 11675842 [TBL] [Abstract][Full Text] [Related]
6. Economic analysis of palivizumab in infants with congenital heart disease. Yount LE; Mahle WT Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622 [TBL] [Abstract][Full Text] [Related]
7. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843 [TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304 [TBL] [Abstract][Full Text] [Related]
9. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623 [TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Groothuis JR; Simoes EA; Hemming VG Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741 [TBL] [Abstract][Full Text] [Related]
11. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Wang D; Bayliss S; Meads C Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564 [TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251 [TBL] [Abstract][Full Text] [Related]
14. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627 [TBL] [Abstract][Full Text] [Related]
15. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Meissner HC; Long SS; Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628 [TBL] [Abstract][Full Text] [Related]
16. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. Numa A J Paediatr Child Health; 2000 Oct; 36(5):422-7. PubMed ID: 11036794 [TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196 [TBL] [Abstract][Full Text] [Related]
18. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Moler FW Pediatrics; 1999 Sep; 104(3 Pt 1):559-60. PubMed ID: 10469785 [No Abstract] [Full Text] [Related]
19. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis. Lee SR; Kwok KL; Ng DKK; Hon KL J Trop Pediatr; 2018 Oct; 64(5):418-425. PubMed ID: 29106671 [TBL] [Abstract][Full Text] [Related]
20. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]